Wal-Fex D Allergy and Decongestant Tablets Recalled for Failed Dissolution
Dr. Reddy's Laboratories is recalling Wal-Fex D Extended Release Tablets nationwide due to failed dissolution specifications. The affected product combines fexofenadine (antihistamine) and pseudoephedrine (decongestant).
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: This is an FDA Class III recall with no reported illnesses or injuries. The hazard is a manufacturing specification failure (failed dissolution) rather than a direct safety threat. The source text does not indicate any known harm to consumers.
Plain-English summary
Dr. Reddy's Laboratories, Inc. is recalling Wal-Fex D Extended Release Tablets containing fexofenadine HCl 60mg and pseudoephedrine HCl 120mg. The recall affects approximately 67,848 boxes distributed nationwide in the USA. The product is being recalled because it failed to meet dissolution specifications.
Affected products are distributed by Walgreen Co. under the following NDC numbers and lot codes: - 20-tablet boxes (NDC 0363-1606-20): Lot #s AC2000968D (Exp. 8/31/2022), AC2103330J (Exp. 1/31/2023), AC2106452A, and AC2106452H (Exp. 3/31/2023) - 30-tablet boxes (NDC 0363-1606-30): Lot #s 79C002624C (Exp. 4/30/2022), AC2103328B, AC2103328C, AC2103330A, and AC2103330B (Exp. 1/31/2023)
Consumers who have purchased this product should stop using it and consult their healthcare provider if they have questions about their treatment.
The recalled product
- Product
- FEXOFENADINE HCL AND PSEUDOEPHEDRINE HCI (FEXOFENADINE HCL AND PSEUDOEPHEDRINE HCI)
- Brand
- FEXOFENADINE HCL AND PSEUDOEPHEDRINE HCI
- Manufacturer
- Dr. Reddy's Laboratories, Inc.
- Hazard
- Affected units
- 67,848
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (13)
- Lot #s: a) (20-count box): AC2000968D
- Exp. 8/31/2022
- AC2103330J
- Exp. 1/31/2023
- AC2106452A
- AC2106452H
- Exp. 3/31/2023. b) (30-count box): 79C002624C
- Exp. 4/30/2022
- AC2103328B
- AC2103328C
- AC2103330A
- AC2103330B
- Exp. 1/31/2023.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 9 recalled by Dr. Reddy's Laboratories, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 9 products in this recall →Related recalls
Same brand · FEXOFENADINE HCL AND PSEUDOEPHEDRINE HCI
- ModerateFexofenadine/Pseudoephedrine tablets recalled for failed dissolution
FDA (Drugs) · 2022-01-26
- ModerateOTC Allergy and Congestion Tablets Recalled for Failed Dissolution
FDA (Drugs) · 2021-12-15
- LowFexofenadine and Pseudoephedrine Tablets Recalled for Failed Dissolution
FDA (Drugs) · 2021-12-15
Same manufacturer · Dr. Reddy's Laboratories, Inc.
See all →- ModerateVarenicline tablets recalled after an assay value fell below specification
FDA (Drugs) · 2025-12-17
- Moderate
- HighOmeprazole capsule bottle contained a foreign divalproex sodium tablet
FDA (Drugs) · 2025-07-23
- SevereLevetiracetam Injection Label Mismatch Nationwide Recall
FDA (Drugs) · 2025-04-23
- ModerateFDA Recalls JAVYGTOR Tablets Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2024-12-18
Same hazard · dissolution failure
See all →- ModerateMylan Recalls Mycophenolate Mofetil Injection Due to Dissolution Failures
FDA (Drugs) · 2026-09-09
- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- ModerateChlorthalidone 25mg tablets failed dissolution specifications in two batches
FDA (Drugs) · 2026-06-24
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17